Amarin withdraws AMR101 MAA for Huntington's

Amarin Corp. plc (NASDAQ:AMRN) withdrew an MAA for AMR101 to treat Huntington's disease after EMEA's CHMP indicated that additional clinical trials would be necessary for approval. Amarin said the company now will concentrate resources on cardiovascular disease and plans to begin Phase III testing next quarter for AMR101 to treat elevated levels of triglycerides. AMR101 is 97% pure ethyl-eicosapentaenoic acid (ethyl-EPA). ...